Current Issue 2018  Archive 2017 
Biography
Biography

Editor-in-Chief of OBM Hepatology and Gastroenterology

Osamu Yokosuka is an Emeritus Professor of Chiba University, Japan. He graduated from Chiba University School of Medicine in 1975 then worked as a trainee under Professor K. Okuda in Chiba University Hospital till 1978. Dr. Yokosuka was a research fellow worked under Professor S. Scherlock and Professor B. H. Billing in Royal Free Hospital, London, UK from 1978 to 1980; under Professor M. Omata in Chiba University from 1980 to 1985; and under Dr. J Summers in Fox Chase Cancer Center, PA, USA in 1984. In 1985, he received a Degree of Doctor of Medical Science, and served as an Assistant Professor in Chiba University till 1994, then as Lecturer in Medicine till 2006 when he was appointed as Director and Professor of Medicine. From 2013 to 2015, he served as the Dean of Chiba University School of Medicine.

Dr. Yokosuka was the Secretary General of APASL (2008-2014). In 2016, he was elected as the President of APASL Tokyo, the President of 52nd Annual Meeting of Japan Society of Hepatology, and the President of Funabashi Central Hospital. Dr. Yokosuka’s research mainly focuses on Hepatitis and Hepatocellular Carcinoma. So far, he has published more than 700 original papers.

Biography

The Associate Editor of OBM Hepatology and Gastroenterology

Tatsuo Kanda received a medical degree in 1991 at Niigata University School of Medicine, Japan, and his PhD in 1999 at Chiba University Graduate School of Medicine, Japan. He had post-doctor training for 3 years under Prof. Ratna Ray and Prof. Ranjit Ray at Saint Louis University, St. Louis, MO, USA. In Dec. 2008, Tatsuo Kanda became a Tenure-track Associate Professor at Department of Medicine and Clinical Oncology, Chiba University, Graduate School of Medicine, Japan. In Feb. 2013, Tatsuo Kanda was nominated a permanent Associate Professor at Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, Japan. In 2017, Tatsuo Kanda became an Associate Professor, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nihon University School of Medicine. For ~25 years, he has focused his scientific interests on the topics related to liver diseases including acute liver failure, viral hepatitis and autoimmune liver diseases, and worked with Prof. Osamu Yokosuka. Tatsuo Kanda is also an expert for hepatitis A virus (HAV), HBV and HCV, and translation and replication of these viruses, and hepatocarcinogenesis. With his expertise in antiviral therapies and hepatitis virus research, Tatsuo Kanda also sees a lot of patients in clinical daily practice. Tatsuo Kanda has published more than 200 articles in peer-reviewed Journal.

Special Issue

Biomarkers in Transplantation

Submission Deadline: November 30, 2018 (Open)               Submit Now

Guest Editor

Mazhar A. Kanak, PhD
Assistant Professor, Transplant Surgery, Department of Surgery, Virginia Commonwealth University School of Medicine, Richmond, VA, USA
E-Mail: [email protected]
Website: https://surgery.vcu.edu/specialties/transplant/kanak.html
Research Interests: Inflammation in islet transplantation; Nuclear Factor Kappa B (NFkB) regulation in inflammatory response; Mechanism of islet rejection; Diabetes Type 1 and 2 development; Biomarkers in transplantation; Tolerance induction; Novel immunosuppression for transplantation; Strategies to improve islet transplantation

About This Topic

Transplantation of organs, tissues, and cells as a cure for life threatening diseases is being performed for several decades now. The major challenge is to keep the graft healthy and alive for the lifetime of the patient. The use of immunosuppression has somewhat favored survival of graft but only temporarily. Detection and management of graft failure early enough to intervene the process of rejection has been widely sought. Biomarkers are molecular, biochemical, or morphological profiles or observations that can be used to monitor graft function, graft loss (acute/chronic), antibody mediated rejection, immune status of the patients etc. Several sources of biomarkers have been explored including protein signatures, mRNA expression, miRNA profiles, cell-free DNA and exosomal analysis. Technological advancement has enabled significant progress towards the development of novel biomarkers. Biomarkers in transplantation can be used to monitor immunosuppression profile, reduce morbidity, improve long-term graft survival and life-expectancy of the patient.

The scope of this special issue will be to introduce the role of biomarkers in transplantation, discuss the biomarkers currently in clinical practice in various forms of transplantation, and demonstrate the use of new technologies and research involved in the development of biomarkers. This special issue is open to all authors involved in the study and development of biomarkers in the area of clinical transplantation.